Why I Think Pfizer Is a Better Buy Than Merck & Co.
Pfizer's products and pipeline opportunity may give it an edge over Merck.
Pfizer(NYSE:PFE) and Merck & Co.(NYSE:MRK) are two of the biggest drugmakers on the planet, and both of these companies reward investors with a healthy dividend yield. But I believe it's Pfizer, not Merck, that ought to be in an investor's portfolio. Here's why... Source: The Motley Fool